Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma (Q81673391)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

Michael J Shulman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Elie A Benaim

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

2280-2286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Complications of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Percutaneous urinary diversion in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Supportive care, pain management, and quality of life in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21054

7 January 2021

Identifiers

DOI

10.1002/CNCR.21054

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15844202%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference